Clinical potential of midostaurin in advanced systemic mastocytosis

Advanced (Ad) systemic mastocytoses (SM) include aggressive SM (ASM) and mast cell leukemia (MCL) with or without an associated clonal hematological non-mast cell lineage disease (AHNMD). They are rare (<15%) but are associated with a poor prognosis due to rapid organ dysfunction. To date, respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandesris, Marie Olivia, Damaj, Gandhi, Lortholary, Olivier, Hermine, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467340/
https://www.ncbi.nlm.nih.gov/pubmed/31360083
http://dx.doi.org/10.2147/BLCTT.S87186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467340/
https://www.ncbi.nlm.nih.gov/pubmed/31360083
http://dx.doi.org/10.2147/BLCTT.S87186

Ejemplares similares